Moderna, INC 10-Q quarterly reports

Moderna reported Q2 2026 results with total revenue increasing to $145 million, driven by other revenue, while net loss slightly narrowed to $782 million.

Moderna reports a $1.34 billion net loss for Q1 2026, driven by a $950 million litigation settlement with Arbutus and Genevant.

Moderna reported a significant revenue decline and net loss in Q3 2025, driven by lower COVID vaccine sales, while advancing its pipeline with new approvals and discontinuations.

Moderna, Inc. reported a significant decrease in net product sales and total revenue for the second quarter and first half of 2025, while simultaneously advancing its respiratory virus vaccine portfolio with new FDA approvals and positive clinical trial results for its seasonal flu vaccine.

Moderna's Q1 2025 revenue decreased due to lower COVID vaccine sales, reflecting the shift to a seasonal respiratory vaccine market, while the company progresses its pipeline and manages costs.

Moderna's Q3 2024 results show stable revenue with significant improvements in profitability due to cost optimization efforts, despite a net loss for the nine-month period.

Moderna's Q2 2024 results show a decrease in revenue due to the evolving COVID-19 vaccine market, alongside the FDA approval of their RSV vaccine.

Moderna's first quarter 2024 results show a significant decrease in revenue due to the evolving COVID-19 vaccine market, with a net loss reported.